Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
NCT06081894Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Primary endpoints: Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score at 36 weeks and Peak Oxygen Uptake at 36 weeks. Started Aug 2023; status: active, not recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06081894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081894.